Literature DB >> 20695800

Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.

James L Raper1, James H Willig, Hui-Yi Lin, Jeroan J Allison, M Bennet Broner, Michael J Mugavero, Michael S Saag.   

Abstract

Although prior authorization (PA) for prescription medications is widely employed for cost-containment for third-party insurers, it is a frustrating aspect of outpatient clinical care that imposes uncompensated costs to medical providers. To characterize these costs, we monitored the PA-associated administrative and operational process at the University of Alabama at Birmingham 1917 HIV Clinic over a 2-year period. A total of 288 PAs were processed with a mean (+/- standard deviation [SD]) of 3.1+/-5.8 days delay in the patient's access to medication. A mean (+/-SD) of 26.8+/-18.4 min was spent by the nurse practitioner and 6.5+/-2.9 min was spent by a clerk per PA. Nearly three-quarters (73%) of PAs were approved, 18% were denied, and 10% were voided. The mean (+/-SD) pages of paperwork was 5.8+/-6.5. The overall cost was $41.60 per PA. Although evidence supports that PA reduces third-party expenditures, it significantly delays medication accessibility for patients and imposes high costs that negatively impact operating margins for health care providers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20695800      PMCID: PMC4892366          DOI: 10.1086/655890

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Approaches to pharmacy benefit management and the impact of consumer cost sharing.

Authors:  Bridget M Olson
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393

2.  Part "D" for "defective"--the Medicare drug-benefit chaos.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

3.  A decade of growth. Salaries increase as profession matures.

Authors:  Jill Rollet; Sarah Lebo
Journal:  Adv Nurse Pract       Date:  2008-01

4.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

5.  Some suffer adjustment pains as Blue Cross changes drug-benefit program on East Coast.

Authors:  N Robb
Journal:  CMAJ       Date:  1995-08-01       Impact factor: 8.262

6.  Distribution of health care expenditures for HIV-infected patients.

Authors:  Ray Y Chen; Neil A Accortt; Andrew O Westfall; Michael J Mugavero; James L Raper; Gretchen A Cloud; Beth K Stone; Jerome Carter; Stephanie Call; Maria Pisu; Jeroan Allison; Michael S Saag
Journal:  Clin Infect Dis       Date:  2006-02-22       Impact factor: 9.079

7.  Gabapentin use in a managed medicaid population.

Authors:  Ann M Hamer; Dean G Haxby; Bentson H McFarland; Kathy Ketchum
Journal:  J Manag Care Pharm       Date:  2002 Jul-Aug

8.  Medicare Part D prescription drug benefits and administrative burden in the care of dually eligible psychiatric patients.

Authors:  Joshua E Wilk; Joyce C West; Donald S Rae; Maritza Rubio-Stipec; Jennifer J Chen; Darrel A Regier
Journal:  Psychiatr Serv       Date:  2008-01       Impact factor: 3.084

Review 9.  How effectively do managed care organizations influence prescribing and dispensing decisions?

Authors:  Norman V Carroll
Journal:  Am J Manag Care       Date:  2002-12       Impact factor: 2.229

  9 in total
  6 in total

1.  Medicare Part D roulette: potential implications of random assignment and plan restrictions.

Authors:  Rajul A Patel; Mark P Walberg; Joseph A Woelfel; Michelle M Amaral; Paresh Varu
Journal:  Medicare Medicaid Res Rev       Date:  2013-04-22

2.  Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study.

Authors:  Zachary S Wallace; Tyler Harkness; Xiaoqing Fu; John H Stone; Hyon K Choi; Rochelle P Walensky
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

3.  Evaluating the effect of prior authorizations in patients with complex dermatologic conditions.

Authors:  Olivia S Jew; Joyce Okawa; John S Barbieri; Joanne McCaffrey; Elizabeth Hayward; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2020-07-02       Impact factor: 11.527

4.  Impact of the removal of the monthly liver function test requirement for ambrisentan.

Authors:  Louise A Durst; John Carlsen; Megan Kuchinski; Lauren Harner; Daniel Neves; Stephanie J Harris; Glenna L Traiger
Journal:  Am Health Drug Benefits       Date:  2012-03

5.  Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention.

Authors:  Alice J Lee; Madeline C Montgomery; Rupa R Patel; Julia Raifman; Lorraine T Dean; Philip A Chan
Journal:  Sex Transm Dis       Date:  2018-04       Impact factor: 3.868

6.  Therapeutic Inertia in Prescribing Biologics for Patients with Moderate-to-Severe Asthma: Workshop Summary.

Authors:  Isabelle P Sico; Amber Oberle; Sheila M Thomas; Thomas Barsanti; Lisa Egbuonu-Davis; Daniel T Kennedy; Leah L Zullig; Hayden B Bosworth
Journal:  Patient Prefer Adherence       Date:  2021-04-07       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.